CoChat

Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Objective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders. Results:CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab.

Overview

Integrity signals

Registry

Crossref · 10.1159/000446819

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 23 · Cited by 10

Metadata

Authors
Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F.
Affiliations
  • St. Joseph’s Healthcare Hamilton (CA)
  • University of Toronto (CA)
  • McMaster University (CA)
Venue
Ophthalmologica
Publisher
S. Karger AG
Published
2016
Volume
236
Issue
2
Pages
88-94
ISSN
  • 0030-3755 (ISSN-L)
  • 1423-0267
OpenAlex
W2469056629
Cited by
10
References
23
Citations by year
2024: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2
FWCI
1.06
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Ophthalmologica (publishedVersion)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
neovascular age-related macular degeneration, ranibizumab, treatment response, complement factor H, single nucleotide polymorphisms, pharmacogenetics, C3 gene, mitochondrial DNA, visual acuity, central macular thickness
MeSH terms
Ranibizumab, Aged, 80 and over, DNA, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Gene Frequency, Genotype, Humans, Male, Prospective Studies, Risk Factors, Time Factors, Genetic Predisposition to Disease, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response. https://app.cochat.ai/papers/10.1159/000446819
The paper
Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F. (2016). Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response. Ophthalmologica. https://doi.org/10.1159/000446819

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.